Last reviewed · How we verify
Shigella sonnei Strain WRSS1 Vaccine
Shigella sonnei Strain WRSS1 Vaccine is a Biologic drug developed by PATH. It is currently in Phase 1 development.
At a glance
| Generic name | Shigella sonnei Strain WRSS1 Vaccine |
|---|---|
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Shigella WRSS1 Vaccine Trial in Bangladesh (PHASE1)
- Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shigella sonnei Strain WRSS1 Vaccine CI brief — competitive landscape report
- Shigella sonnei Strain WRSS1 Vaccine updates RSS · CI watch RSS
- PATH portfolio CI
Frequently asked questions about Shigella sonnei Strain WRSS1 Vaccine
What is Shigella sonnei Strain WRSS1 Vaccine?
Shigella sonnei Strain WRSS1 Vaccine is a Biologic drug developed by PATH.
Who makes Shigella sonnei Strain WRSS1 Vaccine?
Shigella sonnei Strain WRSS1 Vaccine is developed by PATH (see full PATH pipeline at /company/path).
What development phase is Shigella sonnei Strain WRSS1 Vaccine in?
Shigella sonnei Strain WRSS1 Vaccine is in Phase 1.
Related
- Manufacturer: PATH — full pipeline
- Compare: Shigella sonnei Strain WRSS1 Vaccine vs similar drugs
- Pricing: Shigella sonnei Strain WRSS1 Vaccine cost, discount & access